371 / 1631
Summary of Evidence
• Randomized trials in modern era lacking, older studies
inconclusive for role of RT in advanced stage HL.
• RT was given to 35% of patients on EORTC study, and improved EFS
and OS for patients with bulk or incomplete response in SWOG and UK
LY09 study
• Best PET-directed data to inform use HD15 is for BEACOPP –
RT to PET +ve residual disease
• Early stage unfavourable GHSG data illustrate the benefit of RT
is greater with ABVD (compensating for less intensive
chemotherapy), making ongoing randomised PET directed
studies with ABVD critical to decision making.